Positive Results from IH Phase 3 Study of Xywav

Jazz Pharmaceuticals plc announced positive top-line results from their Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of […]

Jazz Pharmaceuticals Announces FDA Approval of Xywav

Jazz Pharmaceuticals plc announced that the US Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy […]